Cargando…
Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study
PURPOSE: Assess the safety, tolerability, and feasibility of subcutaneous administration of the mitochondrial-targeted drug elamipretide in patients with dry age-related macular degeneration (AMD) and noncentral geographic atrophy (NCGA) and to perform exploratory analyses of change in visual functi...
Autores principales: | Mettu, Priyatham S., Allingham, Michael J., Cousins, Scott W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560640/ https://www.ncbi.nlm.nih.gov/pubmed/36246181 http://dx.doi.org/10.1016/j.xops.2021.100086 |
Ejemplares similares
-
Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study
por: Allingham, Michael J., et al.
Publicado: (2021) -
Semiautomatic Segmentation of Rim Area Focal Hyperautofluorescence Predicts Progression of Geographic Atrophy Due to Dry Age-Related Macular Degeneration
por: Allingham, Michael J., et al.
Publicado: (2016) -
Conference of the NCGA
por: National Computer Graphics Association. Washington, DC
Publicado: (1981) -
Choriocapillaris changes in dry age-related macular degeneration and geographic atrophy: a review
por: Arya, Malvika, et al.
Publicado: (2018) -
A Quantitative Approach to Predict Differential Effects of Anti-VEGF Treatment on Diffuse and Focal Leakage in Patients with Diabetic Macular Edema: A Pilot Study
por: Allingham, Michael J., et al.
Publicado: (2017)